Full Text of HB4352 103rd General Assembly
HB4352 103RD GENERAL ASSEMBLY | | | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB4352 Introduced 1/16/2024, by Rep. Tom Weber SYNOPSIS AS INTRODUCED: | | 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 | 720 ILCS 570/206 | from Ch. 56 1/2, par. 1206 |
| Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances. |
| |
| | A BILL FOR |
| | | | HB4352 | | LRB103 35349 RLC 65413 b |
|
| 1 | | AN ACT concerning criminal law. | 2 | | Be it enacted by the People of the State of Illinois, | 3 | | represented in the General Assembly: | 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Sections 204 and 206 as follows: | 6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 7 | | (Text of Section before amendment by P.A. 103-245 ) | 8 | | Sec. 204. (a) The controlled substances listed in this | 9 | | Section are included in Schedule I. | 10 | | (b) Unless specifically excepted or unless listed in | 11 | | another schedule, any of the following opiates, including | 12 | | their isomers, esters, ethers, salts, and salts of isomers, | 13 | | esters, and ethers, whenever the existence of such isomers, | 14 | | esters, ethers and salts is possible within the specific | 15 | | chemical designation: | 16 | | (1) Acetylmethadol; | 17 | | (1.1) Acetyl-alpha-methylfentanyl | 18 | | (N-[1-(1-methyl-2-phenethyl)-
| 19 | | 4-piperidinyl]-N-phenylacetamide); | 20 | | (2) Allylprodine; | 21 | | (3) Alphacetylmethadol, except
| 22 | | levo-alphacetylmethadol (also known as levo-alpha-
| 23 | | acetylmethadol, levomethadyl acetate, or LAAM); |
| | | HB4352 | - 2 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (4) Alphameprodine; | 2 | | (5) Alphamethadol; | 3 | | (6) Alpha-methylfentanyl
| 4 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 5 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 6 | | propanilido) piperidine; | 7 | | (6.1) Alpha-methylthiofentanyl
| 8 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 9 | | 4-piperidinyl]-N-phenylpropanamide); | 10 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 11 | | (7.1) PEPAP
| 12 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 13 | | (8) Benzethidine; | 14 | | (9) Betacetylmethadol; | 15 | | (9.1) Beta-hydroxyfentanyl
| 16 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 17 | | 4-piperidinyl]-N-phenylpropanamide); | 18 | | (10) Betameprodine; | 19 | | (11) Betamethadol; | 20 | | (12) Betaprodine; | 21 | | (13) Clonitazene; | 22 | | (14) Dextromoramide; | 23 | | (15) Diampromide; | 24 | | (16) Diethylthiambutene; | 25 | | (17) Difenoxin; | 26 | | (18) Dimenoxadol; |
| | | HB4352 | - 3 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (19) Dimepheptanol; | 2 | | (20) Dimethylthiambutene; | 3 | | (21) Dioxaphetylbutyrate; | 4 | | (22) Dipipanone; | 5 | | (23) Ethylmethylthiambutene; | 6 | | (24) Etonitazene; | 7 | | (25) Etoxeridine; | 8 | | (26) Furethidine; | 9 | | (27) Hydroxpethidine; | 10 | | (28) Ketobemidone; | 11 | | (29) Levomoramide; | 12 | | (30) Levophenacylmorphan; | 13 | | (31) 3-Methylfentanyl
| 14 | | (N-[3-methyl-1-(2-phenylethyl)-
| 15 | | 4-piperidyl]-N-phenylpropanamide); | 16 | | (31.1) 3-Methylthiofentanyl
| 17 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 18 | | 4-piperidinyl]-N-phenylpropanamide); | 19 | | (32) Morpheridine; | 20 | | (33) Noracymethadol; | 21 | | (34) Norlevorphanol; | 22 | | (35) Normethadone; | 23 | | (36) Norpipanone; | 24 | | (36.1) Para-fluorofentanyl
| 25 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 26 | | 4-piperidinyl]propanamide); |
| | | HB4352 | - 4 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (37) Phenadoxone; | 2 | | (38) Phenampromide; | 3 | | (39) Phenomorphan; | 4 | | (40) Phenoperidine; | 5 | | (41) Piritramide; | 6 | | (42) Proheptazine; | 7 | | (43) Properidine; | 8 | | (44) Propiram; | 9 | | (45) Racemoramide; | 10 | | (45.1) Thiofentanyl
| 11 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 12 | | 4-piperidinyl]-propanamide); | 13 | | (46) Tilidine; | 14 | | (47) Trimeperidine; | 15 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 16 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 17 | | N-phenylpropanamide); | 18 | | (49) Furanyl fentanyl (FU-F); | 19 | | (50) Butyryl fentanyl; | 20 | | (51) Valeryl fentanyl; | 21 | | (52) Acetyl fentanyl; | 22 | | (53) Beta-hydroxy-thiofentanyl; | 23 | | (54) 3,4-dichloro-N-[2-
| 24 | | (dimethylamino)cyclohexyl]-N-
| 25 | | methylbenzamide (U-47700); | 26 | | (55) 4-chloro-N-[1-[2-
|
| | | HB4352 | - 5 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 2 | | benzenesulfonamide (W-18); | 3 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 4 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 5 | | (57) acrylfentanyl (acryloylfentanyl). | 6 | | (c) Unless specifically excepted or unless listed in | 7 | | another schedule, any of the following opium derivatives, its | 8 | | salts, isomers and salts of isomers, whenever the existence of | 9 | | such salts, isomers and salts of isomers is possible within | 10 | | the specific chemical designation: | 11 | | (1) Acetorphine; | 12 | | (2) Acetyldihydrocodeine; | 13 | | (3) Benzylmorphine; | 14 | | (4) Codeine methylbromide; | 15 | | (5) Codeine-N-Oxide; | 16 | | (6) Cyprenorphine; | 17 | | (7) Desomorphine; | 18 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 19 | | (9) Dihydromorphine; | 20 | | (10) Drotebanol; | 21 | | (11) Etorphine (except hydrochloride salt); | 22 | | (12) Heroin; | 23 | | (13) Hydromorphinol; | 24 | | (14) Methyldesorphine; | 25 | | (15) Methyldihydromorphine; | 26 | | (16) Morphine methylbromide; |
| | | HB4352 | - 6 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (17) Morphine methylsulfonate; | 2 | | (18) Morphine-N-Oxide; | 3 | | (19) Myrophine; | 4 | | (20) Nicocodeine; | 5 | | (21) Nicomorphine; | 6 | | (22) Normorphine; | 7 | | (23) Pholcodine; | 8 | | (24) Thebacon. | 9 | | (d) Unless specifically excepted or unless listed in | 10 | | another schedule, any material, compound, mixture, or | 11 | | preparation which contains any quantity of the following | 12 | | hallucinogenic substances, or which contains any of its salts, | 13 | | isomers and salts of isomers, whenever the existence of such | 14 | | salts, isomers, and salts of isomers is possible within the | 15 | | specific chemical designation (for the purposes of this | 16 | | paragraph only, the term "isomer" includes the optical, | 17 | | position and geometric isomers): | 18 | | (1) 3,4-methylenedioxyamphetamine
| 19 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 20 | | methylenedioxyamphetamine, MDA); | 21 | | (1.1) Alpha-ethyltryptamine
| 22 | | (some trade or other names: etryptamine;
| 23 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 24 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 25 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 26 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
| | | HB4352 | - 7 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (also known as: N-ethyl-alpha-methyl-
| 2 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 3 | | and MDEA); | 4 | | (2.2) N-Benzylpiperazine (BZP); | 5 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 6 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 7 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 8 | | (5) (Blank); | 9 | | (6) Diethyltryptamine (DET); | 10 | | (7) Dimethyltryptamine (DMT); | 11 | | (7.1) 5-Methoxy-diallyltryptamine; | 12 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 13 | | (9) Ibogaine (some trade and other names:
| 14 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 15 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 16 | | indole; Tabernanthe iboga); | 17 | | (10) Lysergic acid diethylamide; | 18 | | (10.1) Salvinorin A; | 19 | | (10.5) Salvia divinorum (meaning all parts of the | 20 | | plant presently classified botanically as Salvia | 21 | | divinorum, whether growing or not, the seeds thereof, any | 22 | | extract from any part of that plant, and every compound, | 23 | | manufacture, salts, isomers, and salts of isomers whenever | 24 | | the existence of such salts, isomers, and salts of isomers | 25 | | is possible within the specific chemical designation, | 26 | | derivative, mixture, or preparation of that plant, its |
| | | HB4352 | - 8 - | LRB103 35349 RLC 65413 b |
|
| 1 | | seeds or extracts); | 2 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 3 | | (12) Peyote (meaning all parts of the plant presently | 4 | | classified botanically as Lophophora williamsii Lemaire, | 5 | | whether growing or not, the seeds thereof, any extract | 6 | | from any part of that plant, and every compound, | 7 | | manufacture, salts, derivative, mixture, or preparation of | 8 | | that plant, its seeds or extracts); | 9 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 10 | | (14) N-methyl-3-piperidyl benzilate; | 11 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 12 | | (also known as N-hydroxy-alpha-methyl-
| 13 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 14 | | (15) Parahexyl; some trade or other names:
| 15 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 16 | | dibenzo (b,d) pyran; Synhexyl; | 17 | | (16) Psilocybin; | 18 | | (17) Psilocyn; | 19 | | (18) Alpha-methyltryptamine (AMT); | 20 | | (19) 2,5-dimethoxyamphetamine
| 21 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 22 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 23 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 24 | | 4-bromo-2,5-DMA); | 25 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 26 | | Some trade or other names: 2-(4-bromo-
|
| | | HB4352 | - 9 - | LRB103 35349 RLC 65413 b |
|
| 1 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 2 | | alpha-desmethyl DOB, 2CB, Nexus; | 3 | | (21) 4-methoxyamphetamine
| 4 | | (4-methoxy-alpha-methylphenethylamine;
| 5 | | paramethoxyamphetamine; PMA); | 6 | | (22) (Blank); | 7 | | (23) Ethylamine analog of phencyclidine.
| 8 | | Some trade or other names:
| 9 | | N-ethyl-1-phenylcyclohexylamine,
| 10 | | (1-phenylcyclohexyl) ethylamine,
| 11 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 12 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 13 | | or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 14 | | PHP; | 15 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 16 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 17 | | (another name: DOET); | 18 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 19 | | (another name: TCPy); | 20 | | (28) (Blank); | 21 | | (29) Thiophene analog of phencyclidine (some trade
| 22 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 23 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 24 | | (29.1) Benzothiophene analog of phencyclidine. Some | 25 | | trade or other names: BTCP or benocyclidine; | 26 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
| | | HB4352 | - 10 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (30) Bufotenine (some trade or other names:
| 2 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 3 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 4 | | 5-hydroxy-N,N-dimethyltryptamine;
| 5 | | N,N-dimethylserotonin; mappine); | 6 | | (31) (Blank); | 7 | | (32) (Blank); | 8 | | (33) (Blank); | 9 | | (34) (Blank); | 10 | | (34.5) (Blank); | 11 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 12 | | (2-methyloctan-2-yl)-6a,7, | 13 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 14 | | Some trade or other names: HU-210; | 15 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 16 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 17 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 18 | | salts, and salts of isomers; Some trade or other | 19 | | names: HU-210, Dexanabinol; | 20 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 21 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 22 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 23 | | Some trade or other names: HU-211; | 24 | | (37) (Blank); | 25 | | (38) (Blank); | 26 | | (39) (Blank); |
| | | HB4352 | - 11 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (40) (Blank); | 2 | | (41) (Blank); | 3 | | (42) Any compound structurally derived from | 4 | | 3-(1-naphthoyl)indole or | 5 | | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | 6 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 7 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 8 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 9 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 10 | | in the indole ring to any extent, whether or not | 11 | | substituted in the naphthyl ring to any extent. Examples | 12 | | of this structural class include, but are not limited to, | 13 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | 14 | | (43) Any compound structurally derived from | 15 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 16 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 17 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 18 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 19 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 20 | | in the pyrrole ring to any extent, whether or not | 21 | | substituted in the naphthyl ring to any extent. Examples | 22 | | of this structural class include, but are not limited to, | 23 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | 24 | | (44) Any compound structurally derived from | 25 | | 1-(1-naphthylmethyl)indene by substitution at the | 26 | | 3-position of the indene ring by alkyl, haloalkyl, |
| | | HB4352 | - 12 - | LRB103 35349 RLC 65413 b |
|
| 1 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 2 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 3 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 4 | | in the indene ring to any extent, whether or not | 5 | | substituted in the naphthyl ring to any extent. Examples | 6 | | of this structural class include, but are not limited to, | 7 | | JWH-176; | 8 | | (45) Any compound structurally derived from | 9 | | 3-phenylacetylindole by substitution at the nitrogen atom | 10 | | of the indole ring with alkyl, haloalkyl, alkenyl, | 11 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 12 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | in the indole ring to any extent, whether or not | 15 | | substituted in the phenyl ring to any extent. Examples of | 16 | | this structural class include, but are not limited to, | 17 | | JWH-167, JWH-250, JWH-251, and RCS-8; | 18 | | (46) Any compound structurally derived from | 19 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 20 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 21 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 22 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 23 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the | 24 | | cyclohexyl ring to any extent. Examples of this structural | 25 | | class include, but are not limited to, CP 47, 497 and its | 26 | | C8 homologue (cannabicyclohexanol); |
| | | HB4352 | - 13 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (46.1) Any compound structurally derived from | 2 | | 3-(benzoyl) indole with substitution at the nitrogen atom | 3 | | of the indole ring by an alkyl, haloalkyl, alkenyl, | 4 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 5 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 6 | | 2-(4-morpholinyl)ethyl group whether or not further | 7 | | substituted in the indole ring to any extent and whether | 8 | | or not substituted in the phenyl ring to any extent. | 9 | | Examples of this structural class include, but are not | 10 | | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | 11 | | 48,098), and RCS-4; | 12 | | (47) (Blank); | 13 | | (48) (Blank); | 14 | | (49) (Blank); | 15 | | (50) (Blank); | 16 | | (51) (Blank); | 17 | | (52) (Blank); | 18 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | 19 | | Some trade or other names: 2C-T-7; | 20 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | 21 | | trade or other names: 2C-E; | 22 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | 23 | | trade or other names: 2C-D; | 24 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | 25 | | trade or other names: 2C-C; | 26 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade |
| | | HB4352 | - 14 - | LRB103 35349 RLC 65413 b |
|
| 1 | | or other names: 2C-I; | 2 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | 3 | | trade or other names: 2C-T-2; | 4 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | 5 | | Some trade or other names: 2C-T-4; | 6 | | (53.7) 2,5-dimethoxyphenethylamine. Some trade or | 7 | | other names: 2C-H; | 8 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | 9 | | trade or other names: 2C-N; | 10 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | 11 | | trade or other names: 2C-P; | 12 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | 13 | | Some trade or other names: 2C-G; | 14 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 15 | | phenethylamine referred to in subparagraphs (20.1), (53), | 16 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 17 | | (53.8), (53.9), and (53.10) including, but not limited to, | 18 | | 25I-NBOMe and 25C-NBOMe; | 19 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 20 | | (55) (Blank); | 21 | | (56) (Blank); | 22 | | (57) (Blank); | 23 | | (58) (Blank); | 24 | | (59) 3-cyclopropoylindole with substitution at the | 25 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 26 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
| | | HB4352 | - 15 - | LRB103 35349 RLC 65413 b |
|
| 1 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 3 | | on the indole ring to any extent, whether or not | 4 | | substituted on the cyclopropyl ring to any extent: | 5 | | including, but not limited to, XLR11, UR144, FUB-144; | 6 | | (60) 3-adamantoylindole with substitution at the | 7 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 8 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 9 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 10 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 11 | | on the indole ring to any extent, whether or not | 12 | | substituted on the adamantyl ring to any extent: | 13 | | including, but not limited to, AB-001; | 14 | | (61) N-(adamantyl)-indole-3-carboxamide with | 15 | | substitution at the nitrogen atom of the indole ring by | 16 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 17 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 18 | | 1-(N-methyl-2-piperidinyl)methyl, or | 19 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 20 | | on the indole ring to any extent, whether or not | 21 | | substituted on the adamantyl ring to any extent: | 22 | | including, but not limited to, APICA/2NE-1, STS-135; | 23 | | (62) N-(adamantyl)-indazole-3-carboxamide with | 24 | | substitution at a nitrogen atom of the indazole ring by | 25 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 26 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
| | | HB4352 | - 16 - | LRB103 35349 RLC 65413 b |
|
| 1 | | 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 3 | | on the indazole ring to any extent, whether or not | 4 | | substituted on the adamantyl ring to any extent: | 5 | | including, but not limited to, AKB48, 5F-AKB48; | 6 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | 7 | | with substitution at the nitrogen atom of the indole ring | 8 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 9 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 10 | | 1-(N-methyl-2-piperidinyl)methyl, or | 11 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 12 | | on the indole ring to any extent, whether or not | 13 | | substituted on the quinoline ring to any extent: | 14 | | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | 15 | | (64) 3-(1-naphthoyl)indazole with substitution at the | 16 | | nitrogen atom of the indazole ring by alkyl, haloalkyl, | 17 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 18 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 19 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 20 | | on the indazole ring to any extent, whether or not | 21 | | substituted on the naphthyl ring to any extent: including, | 22 | | but not limited to, THJ-018, THJ-2201; | 23 | | (65) 2-(1-naphthoyl)benzimidazole with substitution | 24 | | at the nitrogen atom of the benzimidazole ring by alkyl, | 25 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 26 | | aryl halide, alkyl aryl halide, |
| | | HB4352 | - 17 - | LRB103 35349 RLC 65413 b |
|
| 1 | | 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 3 | | on the benzimidazole ring to any extent, whether or not | 4 | | substituted on the naphthyl ring to any extent: including, | 5 | | but not limited to, FUBIMINA; | 6 | | (66) | 7 | | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 8 | | 3-carboxamide with substitution on the nitrogen atom of | 9 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 10 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 11 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 12 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 13 | | on the indazole ring to any extent: including, but not | 14 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 15 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 16 | | indazole-3-carboxamide with substitution on the nitrogen | 17 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 18 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 19 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 20 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 21 | | on the indazole ring to any extent: including, but not | 22 | | limited to, ADB-PINACA, ADB-FUBINACA; | 23 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 24 | | indole-3-carboxamide with substitution on the nitrogen | 25 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 26 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
| | | HB4352 | - 18 - | LRB103 35349 RLC 65413 b |
|
| 1 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 3 | | on the indole ring to any extent: including, but not | 4 | | limited to, ADBICA, 5F-ADBICA; | 5 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 6 | | 3-carboxamide with substitution on the nitrogen atom of | 7 | | the indole ring by alkyl, haloalkyl, alkenyl, | 8 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 9 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 10 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 11 | | on the indole ring to any extent: including, but not | 12 | | limited to, ABICA, 5F-ABICA; | 13 | | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | 14 | | methylbutanoate with substitution on the nitrogen atom of | 15 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 16 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 17 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 18 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 19 | | on the indazole ring to any extent: including, but not | 20 | | limited to, AMB, 5F-AMB; | 21 | | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | 22 | | dimethylbutanoate with substitution on the nitrogen atom | 23 | | of the indazole ring by alkyl, haloalkyl, alkenyl, | 24 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 25 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | HB4352 | - 19 - | LRB103 35349 RLC 65413 b |
|
| 1 | | on the indazole ring to any extent: including, but not | 2 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 3 | | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | 4 | | methylbutanoate with substitution on the nitrogen atom of | 5 | | the indole ring by alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indazole ring to any extent: including, but not | 10 | | limited to, MMB018, MMB2201, and AMB-CHMICA; | 11 | | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | 12 | | dimethylbutanoate with substitution on the nitrogen atom | 13 | | of the indole ring by alkyl, haloalkyl, alkenyl, | 14 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 15 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 16 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 17 | | on the indazole ring to any extent: including, but not | 18 | | limited to, MDMB-CHMICA; | 19 | | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | 20 | | indazole-3-carboxamide with substitution on the nitrogen | 21 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 22 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 23 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 25 | | on the indazole ring to any extent: including, but not | 26 | | limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; |
| | | HB4352 | - 20 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | 2 | | 3-carboxamide with substitution on the nitrogen atom of | 3 | | the indole ring by alkyl, haloalkyl, alkenyl, | 4 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 5 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 6 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 7 | | on the indazole ring to any extent: including, but not | 8 | | limited to, APP-PICA and 5-fluoro-APP-PICA; | 9 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 10 | | 4-AcO-DMT; | 11 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | 12 | | name 5-MeO-MIPT; | 13 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 14 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 15 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 16 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine | 17 | | (4-HO-MiPT); | 18 | | (82) Fluorophenylpiperazine; | 19 | | (83) Methoxetamine; | 20 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | 21 | | ethcathinone). | 22 | | (e) Unless specifically excepted or unless listed in | 23 | | another schedule, any material, compound, mixture, or | 24 | | preparation which contains any quantity of the following | 25 | | substances having a depressant effect on the central nervous | 26 | | system, including its salts, isomers, and salts of isomers |
| | | HB4352 | - 21 - | LRB103 35349 RLC 65413 b |
|
| 1 | | whenever the existence of such salts, isomers, and salts of | 2 | | isomers is possible within the specific chemical designation: | 3 | | (1) mecloqualone; | 4 | | (2) methaqualone; and | 5 | | (3) gamma hydroxybutyric acid. | 6 | | (f) Unless specifically excepted or unless listed in | 7 | | another schedule, any material, compound, mixture, or | 8 | | preparation which contains any quantity of the following | 9 | | substances having a stimulant effect on the central nervous | 10 | | system, including its salts, isomers, and salts of isomers: | 11 | | (1) Fenethylline; | 12 | | (2) N-ethylamphetamine; | 13 | | (3) Aminorex (some other names:
| 14 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 15 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 16 | | salts, optical isomers, and salts of optical isomers; | 17 | | (4) Methcathinone (some other names:
| 18 | | 2-methylamino-1-phenylpropan-1-one;
| 19 | | Ephedrone; 2-(methylamino)-propiophenone;
| 20 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 21 | | methycathinone; Monomethylpropion; UR 1431) and its
| 22 | | salts, optical isomers, and salts of optical isomers; | 23 | | (5) Cathinone (some trade or other names:
| 24 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 25 | | 2-amino-1-phenyl-propanone; norephedrone); | 26 | | (6) N,N-dimethylamphetamine (also known as:
|
| | | HB4352 | - 22 - | LRB103 35349 RLC 65413 b |
|
| 1 | | N,N-alpha-trimethyl-benzeneethanamine;
| 2 | | N,N-alpha-trimethylphenethylamine); | 3 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 4 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 5 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | 6 | | (9) Halogenated amphetamines and
| 7 | | methamphetamines - any compound derived from either
| 8 | | amphetamine or methamphetamine through the substitution
| 9 | | of a halogen on the phenyl ring, including, but not
| 10 | | limited to, 2-fluoroamphetamine, 3-
| 11 | | fluoroamphetamine and 4-fluoroamphetamine; | 12 | | (10) Aminopropylbenzofuran (APB):
| 13 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 14 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 15 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; | 16 | | (11) Aminopropyldihydrobenzofuran (APDB):
| 17 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 18 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 19 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| 20 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 21 | | (12) Methylaminopropylbenzofuran
| 22 | | (MAPB): including 4-(2-methylaminopropyl)
| 23 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 24 | | 6-(2-methylaminopropyl)benzofuran
| 25 | | and 7-(2-methylaminopropyl)benzofuran. | 26 | | (g) Temporary listing of substances subject to emergency |
| | | HB4352 | - 23 - | LRB103 35349 RLC 65413 b |
|
| 1 | | scheduling. Any material, compound, mixture, or preparation | 2 | | that contains any quantity of the following substances: | 3 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide | 4 | | (benzylfentanyl), its optical isomers, isomers, salts, and | 5 | | salts of isomers; | 6 | | (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- | 7 | | phenylpropanamide (thenylfentanyl), its optical isomers, | 8 | | salts, and salts of isomers. | 9 | | (h) Synthetic cathinones. Unless specifically excepted, | 10 | | any chemical compound which is not approved by the United | 11 | | States Food and Drug Administration or, if approved, is not | 12 | | dispensed or possessed in accordance with State or federal | 13 | | law, not including bupropion, structurally derived from | 14 | | 2-aminopropan-1-one by substitution at the 1-position with | 15 | | either phenyl, naphthyl, or thiophene ring systems, whether or | 16 | | not the compound is further modified in one or more of the | 17 | | following ways: | 18 | | (1) by substitution in the ring system to any extent | 19 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | 20 | | halide substituents, whether or not further substituted in | 21 | | the ring system by one or more other univalent | 22 | | substituents. Examples of this class include, but are not | 23 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | 24 | | (2) by substitution at the 3-position with an acyclic | 25 | | alkyl substituent. Examples of this class include, but are | 26 | | not limited to, 2-methylamino-1-phenylbutan-1-one |
| | | HB4352 | - 24 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (buphedrone); or | 2 | | (3) by substitution at the 2-amino nitrogen atom with | 3 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | 4 | | inclusion of the 2-amino nitrogen atom in a cyclic | 5 | | structure. Examples of this class include, but are not | 6 | | limited to, Dimethylcathinone, Ethcathinone, and | 7 | | a-Pyrrolidinopropiophenone (a-PPP); or | 8 | | Any other synthetic cathinone which is not approved by the | 9 | | United States Food and Drug Administration or, if approved, is | 10 | | not dispensed or possessed in accordance with State or federal | 11 | | law. | 12 | | (i) Synthetic cannabinoids or piperazines. Any synthetic | 13 | | cannabinoid or piperazine which is not approved by the United | 14 | | States Food and Drug Administration or, if approved, which is | 15 | | not dispensed or possessed in accordance with State and | 16 | | federal law. | 17 | | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | 18 | | 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | 19 | | 8-14-18 .) | 20 | | (Text of Section after amendment by P.A. 103-245 ) | 21 | | Sec. 204. (a) The controlled substances listed in this | 22 | | Section are included in Schedule I. | 23 | | (b) Unless specifically excepted or unless listed in | 24 | | another schedule, any of the following opiates, including | 25 | | their isomers, esters, ethers, salts, and salts of isomers, |
| | | HB4352 | - 25 - | LRB103 35349 RLC 65413 b |
|
| 1 | | esters, and ethers, whenever the existence of such isomers, | 2 | | esters, ethers and salts is possible within the specific | 3 | | chemical designation: | 4 | | (1) Acetylmethadol; | 5 | | (1.1) Acetyl-alpha-methylfentanyl | 6 | | (N-[1-(1-methyl-2-phenethyl)-
| 7 | | 4-piperidinyl]-N-phenylacetamide); | 8 | | (2) Allylprodine; | 9 | | (3) Alphacetylmethadol, except
| 10 | | levo-alphacetylmethadol (also known as levo-alpha-
| 11 | | acetylmethadol, levomethadyl acetate, or LAAM); | 12 | | (4) Alphameprodine; | 13 | | (5) Alphamethadol; | 14 | | (6) Alpha-methylfentanyl
| 15 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 16 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 17 | | propanilido) piperidine; | 18 | | (6.1) Alpha-methylthiofentanyl
| 19 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 20 | | 4-piperidinyl]-N-phenylpropanamide); | 21 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 22 | | (7.1) PEPAP
| 23 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 24 | | (8) Benzethidine; | 25 | | (9) Betacetylmethadol; | 26 | | (9.1) Beta-hydroxyfentanyl
|
| | | HB4352 | - 26 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 2 | | 4-piperidinyl]-N-phenylpropanamide); | 3 | | (10) Betameprodine; | 4 | | (11) Betamethadol; | 5 | | (12) Betaprodine; | 6 | | (13) Clonitazene; | 7 | | (14) Dextromoramide; | 8 | | (15) Diampromide; | 9 | | (16) Diethylthiambutene; | 10 | | (17) Difenoxin; | 11 | | (18) Dimenoxadol; | 12 | | (19) Dimepheptanol; | 13 | | (20) Dimethylthiambutene; | 14 | | (21) Dioxaphetylbutyrate; | 15 | | (22) Dipipanone; | 16 | | (23) Ethylmethylthiambutene; | 17 | | (24) Etonitazene; | 18 | | (25) Etoxeridine; | 19 | | (26) Furethidine; | 20 | | (27) Hydroxpethidine; | 21 | | (28) Ketobemidone; | 22 | | (29) Levomoramide; | 23 | | (30) Levophenacylmorphan; | 24 | | (31) 3-Methylfentanyl
| 25 | | (N-[3-methyl-1-(2-phenylethyl)-
| 26 | | 4-piperidyl]-N-phenylpropanamide); |
| | | HB4352 | - 27 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (31.1) 3-Methylthiofentanyl
| 2 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 3 | | 4-piperidinyl]-N-phenylpropanamide); | 4 | | (32) Morpheridine; | 5 | | (33) Noracymethadol; | 6 | | (34) Norlevorphanol; | 7 | | (35) Normethadone; | 8 | | (36) Norpipanone; | 9 | | (36.1) Para-fluorofentanyl
| 10 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 11 | | 4-piperidinyl]propanamide); | 12 | | (37) Phenadoxone; | 13 | | (38) Phenampromide; | 14 | | (39) Phenomorphan; | 15 | | (40) Phenoperidine; | 16 | | (41) Piritramide; | 17 | | (42) Proheptazine; | 18 | | (43) Properidine; | 19 | | (44) Propiram; | 20 | | (45) Racemoramide; | 21 | | (45.1) Thiofentanyl
| 22 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 23 | | 4-piperidinyl]-propanamide); | 24 | | (46) Tilidine; | 25 | | (47) Trimeperidine; | 26 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
|
| | | HB4352 | - 28 - | LRB103 35349 RLC 65413 b |
|
| 1 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 2 | | N-phenylpropanamide); | 3 | | (49) Furanyl fentanyl (FU-F); | 4 | | (50) Butyryl fentanyl; | 5 | | (51) Valeryl fentanyl; | 6 | | (52) Acetyl fentanyl; | 7 | | (53) Beta-hydroxy-thiofentanyl; | 8 | | (54) 3,4-dichloro-N-[2-
| 9 | | (dimethylamino)cyclohexyl]-N-
| 10 | | methylbenzamide (U-47700); | 11 | | (55) 4-chloro-N-[1-[2-
| 12 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 13 | | benzenesulfonamide (W-18); | 14 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 15 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 16 | | (57) acrylfentanyl (acryloylfentanyl). | 17 | | (c) Unless specifically excepted or unless listed in | 18 | | another schedule, any of the following opium derivatives, its | 19 | | salts, isomers and salts of isomers, whenever the existence of | 20 | | such salts, isomers and salts of isomers is possible within | 21 | | the specific chemical designation: | 22 | | (1) Acetorphine; | 23 | | (2) Acetyldihydrocodeine; | 24 | | (3) Benzylmorphine; | 25 | | (4) Codeine methylbromide; | 26 | | (5) Codeine-N-Oxide; |
| | | HB4352 | - 29 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (6) Cyprenorphine; | 2 | | (7) Desomorphine; | 3 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 4 | | (9) Dihydromorphine; | 5 | | (10) Drotebanol; | 6 | | (11) Etorphine (except hydrochloride salt); | 7 | | (12) Heroin; | 8 | | (13) Hydromorphinol; | 9 | | (14) Methyldesorphine; | 10 | | (15) Methyldihydromorphine; | 11 | | (16) Morphine methylbromide; | 12 | | (17) Morphine methylsulfonate; | 13 | | (18) Morphine-N-Oxide; | 14 | | (19) Myrophine; | 15 | | (20) Nicocodeine; | 16 | | (21) Nicomorphine; | 17 | | (22) Normorphine; | 18 | | (23) Pholcodine; | 19 | | (24) Thebacon. | 20 | | (d) Unless specifically excepted or unless listed in | 21 | | another schedule, any material, compound, mixture, or | 22 | | preparation which contains any quantity of the following | 23 | | hallucinogenic substances, or which contains any of its salts, | 24 | | isomers and salts of isomers, whenever the existence of such | 25 | | salts, isomers, and salts of isomers is possible within the | 26 | | specific chemical designation (for the purposes of this |
| | | HB4352 | - 30 - | LRB103 35349 RLC 65413 b |
|
| 1 | | paragraph only, the term "isomer" includes the optical, | 2 | | position and geometric isomers): | 3 | | (1) 3,4-methylenedioxyamphetamine
| 4 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 5 | | methylenedioxyamphetamine, MDA); | 6 | | (1.1) Alpha-ethyltryptamine
| 7 | | (some trade or other names: etryptamine;
| 8 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 9 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 10 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 11 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 12 | | (also known as: N-ethyl-alpha-methyl-
| 13 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 14 | | and MDEA); | 15 | | (2.2) N-Benzylpiperazine (BZP); | 16 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 17 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 18 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 19 | | (5) (Blank); | 20 | | (6) Diethyltryptamine (DET); | 21 | | (7) Dimethyltryptamine (DMT); | 22 | | (7.1) 5-Methoxy-diallyltryptamine; | 23 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 24 | | (9) Ibogaine (some trade and other names:
| 25 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 26 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
| | | HB4352 | - 31 - | LRB103 35349 RLC 65413 b |
|
| 1 | | indole; Tabernanthe iboga); | 2 | | (10) Lysergic acid diethylamide; | 3 | | (10.1) Salvinorin A; | 4 | | (10.5) Salvia divinorum (meaning all parts of the | 5 | | plant presently classified botanically as Salvia | 6 | | divinorum, whether growing or not, the seeds thereof, any | 7 | | extract from any part of that plant, and every compound, | 8 | | manufacture, salts, isomers, and salts of isomers whenever | 9 | | the existence of such salts, isomers, and salts of isomers | 10 | | is possible within the specific chemical designation, | 11 | | derivative, mixture, or preparation of that plant, its | 12 | | seeds or extracts); | 13 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 14 | | (12) Peyote (meaning all parts of the plant presently | 15 | | classified botanically as Lophophora williamsii Lemaire, | 16 | | whether growing or not, the seeds thereof, any extract | 17 | | from any part of that plant, and every compound, | 18 | | manufacture, salts, derivative, mixture, or preparation of | 19 | | that plant, its seeds or extracts); | 20 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 21 | | (14) N-methyl-3-piperidyl benzilate; | 22 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 23 | | (also known as N-hydroxy-alpha-methyl-
| 24 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 25 | | (15) Parahexyl; some trade or other names:
| 26 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
| | | HB4352 | - 32 - | LRB103 35349 RLC 65413 b |
|
| 1 | | dibenzo (b,d) pyran; Synhexyl; | 2 | | (16) Psilocybin; | 3 | | (17) Psilocyn; | 4 | | (18) Alpha-methyltryptamine (AMT); | 5 | | (19) 2,5-dimethoxyamphetamine
| 6 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 7 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 8 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 9 | | 4-bromo-2,5-DMA); | 10 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 11 | | Some trade or other names: 2-(4-bromo-
| 12 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 13 | | alpha-desmethyl DOB, 2CB, Nexus; | 14 | | (21) 4-methoxyamphetamine
| 15 | | (4-methoxy-alpha-methylphenethylamine;
| 16 | | paramethoxyamphetamine; PMA); | 17 | | (22) (Blank); | 18 | | (23) Ethylamine analog of phencyclidine.
| 19 | | Some trade or other names:
| 20 | | N-ethyl-1-phenylcyclohexylamine,
| 21 | | (1-phenylcyclohexyl) ethylamine,
| 22 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 23 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 24 | | or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 25 | | PHP; | 26 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
| | | HB4352 | - 33 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 2 | | (another name: DOET); | 3 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 4 | | (another name: TCPy); | 5 | | (28) (Blank); | 6 | | (29) Thiophene analog of phencyclidine (some trade
| 7 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 8 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 9 | | (29.1) Benzothiophene analog of phencyclidine. Some | 10 | | trade or other names: BTCP or benocyclidine; | 11 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | 12 | | (30) Bufotenine (some trade or other names:
| 13 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 14 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 15 | | 5-hydroxy-N,N-dimethyltryptamine;
| 16 | | N,N-dimethylserotonin; mappine); | 17 | | (31) (Blank); | 18 | | (32) (Blank); | 19 | | (33) (Blank); | 20 | | (34) (Blank); | 21 | | (34.5) (Blank); | 22 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 23 | | (2-methyloctan-2-yl)-6a,7, | 24 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 25 | | Some trade or other names: HU-210; | 26 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
| | | HB4352 | - 34 - | LRB103 35349 RLC 65413 b |
|
| 1 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 2 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 3 | | salts, and salts of isomers; Some trade or other | 4 | | names: HU-210, Dexanabinol; | 5 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 6 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 7 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 8 | | Some trade or other names: HU-211; | 9 | | (37) (Blank); | 10 | | (38) (Blank); | 11 | | (39) (Blank); | 12 | | (40) (Blank); | 13 | | (41) (Blank); | 14 | | (42) Any compound structurally derived from | 15 | | 3-(1-naphthoyl)indole or | 16 | | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | 17 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 18 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 19 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 20 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 21 | | in the indole ring to any extent, whether or not | 22 | | substituted in the naphthyl ring to any extent. Examples | 23 | | of this structural class include, but are not limited to, | 24 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | 25 | | (43) Any compound structurally derived from | 26 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
| | | HB4352 | - 35 - | LRB103 35349 RLC 65413 b |
|
| 1 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 2 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 3 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 4 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 5 | | in the pyrrole ring to any extent, whether or not | 6 | | substituted in the naphthyl ring to any extent. Examples | 7 | | of this structural class include, but are not limited to, | 8 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | 9 | | (44) Any compound structurally derived from | 10 | | 1-(1-naphthylmethyl)indene by substitution at the | 11 | | 3-position of the indene ring by alkyl, haloalkyl, | 12 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 13 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 14 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 15 | | in the indene ring to any extent, whether or not | 16 | | substituted in the naphthyl ring to any extent. Examples | 17 | | of this structural class include, but are not limited to, | 18 | | JWH-176; | 19 | | (45) Any compound structurally derived from | 20 | | 3-phenylacetylindole by substitution at the nitrogen atom | 21 | | of the indole ring with alkyl, haloalkyl, alkenyl, | 22 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 23 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 25 | | in the indole ring to any extent, whether or not | 26 | | substituted in the phenyl ring to any extent. Examples of |
| | | HB4352 | - 36 - | LRB103 35349 RLC 65413 b |
|
| 1 | | this structural class include, but are not limited to, | 2 | | JWH-167, JWH-250, JWH-251, and RCS-8; | 3 | | (46) Any compound structurally derived from | 4 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 5 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 6 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 7 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the | 9 | | cyclohexyl ring to any extent. Examples of this structural | 10 | | class include, but are not limited to, CP 47, 497 and its | 11 | | C8 homologue (cannabicyclohexanol); | 12 | | (46.1) Any compound structurally derived from | 13 | | 3-(benzoyl) indole with substitution at the nitrogen atom | 14 | | of the indole ring by an alkyl, haloalkyl, alkenyl, | 15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl group whether or not further | 18 | | substituted in the indole ring to any extent and whether | 19 | | or not substituted in the phenyl ring to any extent. | 20 | | Examples of this structural class include, but are not | 21 | | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | 22 | | 48,098), and RCS-4; | 23 | | (47) (Blank); | 24 | | (48) (Blank); | 25 | | (49) (Blank); | 26 | | (50) (Blank); |
| | | HB4352 | - 37 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (51) (Blank); | 2 | | (52) (Blank); | 3 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | 4 | | Some trade or other names: 2C-T-7; | 5 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | 6 | | trade or other names: 2C-E; | 7 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | 8 | | trade or other names: 2C-D; | 9 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | 10 | | trade or other names: 2C-C; | 11 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | 12 | | or other names: 2C-I; | 13 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | 14 | | trade or other names: 2C-T-2; | 15 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | 16 | | Some trade or other names: 2C-T-4; | 17 | | (53.7) 2,5-dimethoxyphenethylamine. Some trade or | 18 | | other names: 2C-H; | 19 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | 20 | | trade or other names: 2C-N; | 21 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | 22 | | trade or other names: 2C-P; | 23 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | 24 | | Some trade or other names: 2C-G; | 25 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 26 | | phenethylamine referred to in subparagraphs (20.1), (53), |
| | | HB4352 | - 38 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 2 | | (53.8), (53.9), and (53.10) including, but not limited to, | 3 | | 25I-NBOMe and 25C-NBOMe; | 4 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 5 | | (55) (Blank); | 6 | | (56) (Blank); | 7 | | (57) (Blank); | 8 | | (58) (Blank); | 9 | | (59) 3-cyclopropoylindole with substitution at the | 10 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 11 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 12 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | on the indole ring to any extent, whether or not | 15 | | substituted on the cyclopropyl ring to any extent: | 16 | | including, but not limited to, XLR11, UR144, FUB-144; | 17 | | (60) 3-adamantoylindole with substitution at the | 18 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 19 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 20 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 22 | | on the indole ring to any extent, whether or not | 23 | | substituted on the adamantyl ring to any extent: | 24 | | including, but not limited to, AB-001; | 25 | | (61) N-(adamantyl)-indole-3-carboxamide with | 26 | | substitution at the nitrogen atom of the indole ring by |
| | | HB4352 | - 39 - | LRB103 35349 RLC 65413 b |
|
| 1 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 2 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 3 | | 1-(N-methyl-2-piperidinyl)methyl, or | 4 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 5 | | on the indole ring to any extent, whether or not | 6 | | substituted on the adamantyl ring to any extent: | 7 | | including, but not limited to, APICA/2NE-1, STS-135; | 8 | | (62) N-(adamantyl)-indazole-3-carboxamide with | 9 | | substitution at a nitrogen atom of the indazole ring by | 10 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 11 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 12 | | 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | on the indazole ring to any extent, whether or not | 15 | | substituted on the adamantyl ring to any extent: | 16 | | including, but not limited to, AKB48, 5F-AKB48; | 17 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | 18 | | with substitution at the nitrogen atom of the indole ring | 19 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 20 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 23 | | on the indole ring to any extent, whether or not | 24 | | substituted on the quinoline ring to any extent: | 25 | | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | 26 | | (64) 3-(1-naphthoyl)indazole with substitution at the |
| | | HB4352 | - 40 - | LRB103 35349 RLC 65413 b |
|
| 1 | | nitrogen atom of the indazole ring by alkyl, haloalkyl, | 2 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 3 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 4 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 5 | | on the indazole ring to any extent, whether or not | 6 | | substituted on the naphthyl ring to any extent: including, | 7 | | but not limited to, THJ-018, THJ-2201; | 8 | | (65) 2-(1-naphthoyl)benzimidazole with substitution | 9 | | at the nitrogen atom of the benzimidazole ring by alkyl, | 10 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 11 | | aryl halide, alkyl aryl halide, | 12 | | 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | on the benzimidazole ring to any extent, whether or not | 15 | | substituted on the naphthyl ring to any extent: including, | 16 | | but not limited to, FUBIMINA; | 17 | | (66) | 18 | | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 19 | | 3-carboxamide with substitution on the nitrogen atom of | 20 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 21 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 22 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 23 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 24 | | on the indazole ring to any extent: including, but not | 25 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 26 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
| | | HB4352 | - 41 - | LRB103 35349 RLC 65413 b |
|
| 1 | | indazole-3-carboxamide with substitution on the nitrogen | 2 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 3 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 4 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 6 | | on the indazole ring to any extent: including, but not | 7 | | limited to, ADB-PINACA, ADB-FUBINACA; | 8 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 9 | | indole-3-carboxamide with substitution on the nitrogen | 10 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 11 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 12 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 14 | | on the indole ring to any extent: including, but not | 15 | | limited to, ADBICA, 5F-ADBICA; | 16 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 17 | | 3-carboxamide with substitution on the nitrogen atom of | 18 | | the indole ring by alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 20 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 22 | | on the indole ring to any extent: including, but not | 23 | | limited to, ABICA, 5F-ABICA; | 24 | | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | 25 | | methylbutanoate with substitution on the nitrogen atom of | 26 | | the indazole ring by alkyl, haloalkyl, alkenyl, |
| | | HB4352 | - 42 - | LRB103 35349 RLC 65413 b |
|
| 1 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 2 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 3 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 4 | | on the indazole ring to any extent: including, but not | 5 | | limited to, AMB, 5F-AMB; | 6 | | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | 7 | | dimethylbutanoate with substitution on the nitrogen atom | 8 | | of the indazole ring by alkyl, haloalkyl, alkenyl, | 9 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 10 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 11 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 12 | | on the indazole ring to any extent: including, but not | 13 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 14 | | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | 15 | | methylbutanoate with substitution on the nitrogen atom of | 16 | | the indole ring by alkyl, haloalkyl, alkenyl, | 17 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 18 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 19 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 20 | | on the indazole ring to any extent: including, but not | 21 | | limited to, MMB018, MMB2201, and AMB-CHMICA; | 22 | | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | 23 | | dimethylbutanoate with substitution on the nitrogen atom | 24 | | of the indole ring by alkyl, haloalkyl, alkenyl, | 25 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 26 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
| | | HB4352 | - 43 - | LRB103 35349 RLC 65413 b |
|
| 1 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 2 | | on the indazole ring to any extent: including, but not | 3 | | limited to, MDMB-CHMICA; | 4 | | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | 5 | | indazole-3-carboxamide with substitution on the nitrogen | 6 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 7 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 8 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 9 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 10 | | on the indazole ring to any extent: including, but not | 11 | | limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; | 12 | | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | 13 | | 3-carboxamide with substitution on the nitrogen atom of | 14 | | the indole ring by alkyl, haloalkyl, alkenyl, | 15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indazole ring to any extent: including, but not | 19 | | limited to, APP-PICA and 5-fluoro-APP-PICA; | 20 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 21 | | 4-AcO-DMT; | 22 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | 23 | | name 5-MeO-MIPT; | 24 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 25 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 26 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); |
| | | HB4352 | - 44 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine | 2 | | (4-HO-MiPT); | 3 | | (82) Fluorophenylpiperazine; | 4 | | (83) Methoxetamine; | 5 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | 6 | | ethcathinone). | 7 | | (e) Unless specifically excepted or unless listed in | 8 | | another schedule, any material, compound, mixture, or | 9 | | preparation which contains any quantity of the following | 10 | | substances having a depressant effect on the central nervous | 11 | | system, including its salts, isomers, and salts of isomers | 12 | | whenever the existence of such salts, isomers, and salts of | 13 | | isomers is possible within the specific chemical designation: | 14 | | (1) mecloqualone; | 15 | | (2) methaqualone; and | 16 | | (3) gamma hydroxybutyric acid. | 17 | | (f) Unless specifically excepted or unless listed in | 18 | | another schedule, any material, compound, mixture, or | 19 | | preparation which contains any quantity of the following | 20 | | substances having a stimulant effect on the central nervous | 21 | | system, including its salts, isomers, and salts of isomers: | 22 | | (1) Fenethylline; | 23 | | (2) N-ethylamphetamine; | 24 | | (3) Aminorex (some other names:
| 25 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 26 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
| | | HB4352 | - 45 - | LRB103 35349 RLC 65413 b |
|
| 1 | | salts, optical isomers, and salts of optical isomers; | 2 | | (4) Methcathinone (some other names:
| 3 | | 2-methylamino-1-phenylpropan-1-one;
| 4 | | Ephedrone; 2-(methylamino)-propiophenone;
| 5 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 6 | | methycathinone; Monomethylpropion; UR 1431) and its
| 7 | | salts, optical isomers, and salts of optical isomers; | 8 | | (5) Cathinone (some trade or other names:
| 9 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 10 | | 2-amino-1-phenyl-propanone; norephedrone); | 11 | | (6) N,N-dimethylamphetamine (also known as:
| 12 | | N,N-alpha-trimethyl-benzeneethanamine;
| 13 | | N,N-alpha-trimethylphenethylamine); | 14 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 15 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 16 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | 17 | | (9) Halogenated amphetamines and
| 18 | | methamphetamines - any compound derived from either
| 19 | | amphetamine or methamphetamine through the substitution
| 20 | | of a halogen on the phenyl ring, including, but not
| 21 | | limited to, 2-fluoroamphetamine, 3-
| 22 | | fluoroamphetamine and 4-fluoroamphetamine; | 23 | | (10) Aminopropylbenzofuran (APB):
| 24 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 25 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 26 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; |
| | | HB4352 | - 46 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (11) Aminopropyldihydrobenzofuran (APDB):
| 2 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 3 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 4 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| 5 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 6 | | (12) Methylaminopropylbenzofuran
| 7 | | (MAPB): including 4-(2-methylaminopropyl)
| 8 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 9 | | 6-(2-methylaminopropyl)benzofuran
| 10 | | and 7-(2-methylaminopropyl)benzofuran. | 11 | | (g) Temporary listing of substances subject to emergency | 12 | | scheduling. Any material, compound, mixture, or preparation | 13 | | that contains any quantity of the following substances: | 14 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide | 15 | | (benzylfentanyl), its optical isomers, isomers, salts, and | 16 | | salts of isomers; | 17 | | (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- | 18 | | phenylpropanamide (thenylfentanyl), its optical isomers, | 19 | | salts, and salts of isomers. | 20 | | (h) Synthetic cathinones. Unless specifically excepted, | 21 | | any chemical compound which is not approved by the United | 22 | | States Food and Drug Administration or, if approved, is not | 23 | | dispensed or possessed in accordance with State or federal | 24 | | law, not including bupropion, structurally derived from | 25 | | 2-aminopropan-1-one by substitution at the 1-position with | 26 | | either phenyl, naphthyl, or thiophene ring systems, whether or |
| | | HB4352 | - 47 - | LRB103 35349 RLC 65413 b |
|
| 1 | | not the compound is further modified in one or more of the | 2 | | following ways: | 3 | | (1) by substitution in the ring system to any extent | 4 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | 5 | | halide substituents, whether or not further substituted in | 6 | | the ring system by one or more other univalent | 7 | | substituents. Examples of this class include, but are not | 8 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | 9 | | (2) by substitution at the 3-position with an acyclic | 10 | | alkyl substituent. Examples of this class include, but are | 11 | | not limited to, 2-methylamino-1-phenylbutan-1-one | 12 | | (buphedrone); or | 13 | | (3) by substitution at the 2-amino nitrogen atom with | 14 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | 15 | | inclusion of the 2-amino nitrogen atom in a cyclic | 16 | | structure. Examples of this class include, but are not | 17 | | limited to, Dimethylcathinone, Ethcathinone, and | 18 | | a-Pyrrolidinopropiophenone (a-PPP); or | 19 | | Any other synthetic cathinone which is not approved by the | 20 | | United States Food and Drug Administration or, if approved, is | 21 | | not dispensed or possessed in accordance with State or federal | 22 | | law. | 23 | | (i) Synthetic cannabinoids or piperazines. Any synthetic | 24 | | cannabinoid or piperazine which is not approved by the United | 25 | | States Food and Drug Administration or, if approved, which is | 26 | | not dispensed or possessed in accordance with State and |
| | | HB4352 | - 48 - | LRB103 35349 RLC 65413 b |
|
| 1 | | federal law. | 2 | | (j) Unless specifically excepted or listed in another | 3 | | schedule, any chemical compound which is not approved by the | 4 | | United States Food and Drug Administration or, if approved, is | 5 | | not dispensed or possessed in accordance with State or federal | 6 | | law, and is derived from the following structural classes and | 7 | | their salts: | 8 | | (1) Benzodiazepine class: A fused 1,4-diazepine and | 9 | | benzene ring structure with a phenyl connected to the | 10 | | 1,4-diazepine ring, with any substitution(s) or | 11 | | replacement(s) on the 1,4-diazepine or benzene ring, any | 12 | | substitution(s) on the phenyl ring, or any combination | 13 | | thereof. Examples of this class include but are not | 14 | | limited to: Clonazolam, Flualprazolam; or | 15 | | (2) Thienodiazepine class: A fused 1,4-diazepine and | 16 | | thiophene ring structure with a phenyl connected to the | 17 | | 1,4-diazepine ring, with any substitution(s) or | 18 | | replacement(s) on the 1,4-diazepine or thiophene ring, any | 19 | | substitution(s) on the phenyl ring, or any combination | 20 | | thereof. Examples of this class include but are not | 21 | | limited to: Etizolam. | 22 | | (Source: P.A. 103-245, eff. 1-1-24.) | 23 | | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206) | 24 | | Sec. 206. (a) The controlled substances listed in this | 25 | | Section are included in Schedule II. |
| | | HB4352 | - 49 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (b) Unless specifically excepted or unless listed in | 2 | | another schedule, any of the following substances whether | 3 | | produced directly or indirectly by extraction from substances | 4 | | of vegetable origin, or independently by means of chemical | 5 | | synthesis, or by combination of extraction and chemical | 6 | | synthesis: | 7 | | (1) Opium and opiates, and any salt, compound, | 8 | | derivative or preparation of opium or opiate, excluding | 9 | | apomorphine, dextrorphan, levopropoxyphene, nalbuphine, | 10 | | nalmefene, naloxone, and naltrexone, and their respective | 11 | | salts, but including the following: | 12 | | (i) Raw Opium; | 13 | | (ii) Opium extracts; | 14 | | (iii) Opium fluid extracts; | 15 | | (iv) Powdered opium; | 16 | | (v) Granulated opium; | 17 | | (vi) Tincture of opium; | 18 | | (vii) Codeine; | 19 | | (viii) Ethylmorphine; | 20 | | (ix) Etorphine Hydrochloride; | 21 | | (x) Hydrocodone; | 22 | | (xi) Hydromorphone; | 23 | | (xii) Metopon; | 24 | | (xiii) Morphine; | 25 | | (xiii.5) 6-Monoacetylmorphine; | 26 | | (xiv) Oxycodone; |
| | | HB4352 | - 50 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (xv) Oxymorphone; | 2 | | (xv.5) Tapentadol; | 3 | | (xvi) Thebaine; | 4 | | (xvii) Thebaine-derived butorphanol. | 5 | | (xviii) Methorphan, except drug products | 6 | | containing dextromethorphan that may be dispensed | 7 | | pursuant to a prescription order of a practitioner and | 8 | | are sold in compliance with the safety and labeling | 9 | | standards as set forth by the United States Food and | 10 | | Drug Administration, or drug products containing | 11 | | dextromethorphan that are sold in solid, tablet, | 12 | | liquid, capsule, powder, thin film, or gel form and | 13 | | which are formulated, packaged, and sold in dosages | 14 | | and concentrations for use as an over-the-counter drug | 15 | | product. For the purposes of this Section, | 16 | | "over-the-counter drug product" means a drug that is | 17 | | available to consumers without a prescription and sold | 18 | | in compliance with the safety and labeling standards | 19 | | as set forth by the United States Food and Drug | 20 | | Administration. | 21 | | (2) Any salt, compound, isomer, derivative or | 22 | | preparation thereof which is chemically equivalent or | 23 | | identical with any of the substances referred to in | 24 | | subparagraph (1), but not including the isoquinoline | 25 | | alkaloids of opium; | 26 | | (3) Opium poppy and poppy straw; |
| | | HB4352 | - 51 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (4) Coca leaves and any salt, compound, isomer, salt | 2 | | of an isomer, derivative, or preparation of coca leaves | 3 | | including cocaine or ecgonine, and any salt, compound, | 4 | | isomer, derivative, or preparation thereof which is | 5 | | chemically equivalent or identical with any of these | 6 | | substances, but not including decocainized coca leaves or | 7 | | extractions of coca leaves which do not contain cocaine or | 8 | | ecgonine (for the purpose of this paragraph, the term | 9 | | "isomer" includes optical, positional and geometric | 10 | | isomers); | 11 | | (5) Concentrate of poppy straw (the crude extract of | 12 | | poppy straw in either liquid, solid or powder form which | 13 | | contains the phenanthrine alkaloids of the opium poppy). | 14 | | (c) Unless specifically excepted or unless listed in | 15 | | another schedule any of the following opiates, including their | 16 | | isomers, esters, ethers, salts, and salts of isomers, whenever | 17 | | the existence of these isomers, esters, ethers and salts is | 18 | | possible within the specific chemical designation, dextrorphan | 19 | | excepted: | 20 | | (1) Alfentanil; | 21 | | (1.1) Carfentanil; | 22 | | (1.2) Thiafentanyl; | 23 | | (2) Alphaprodine; | 24 | | (3) Anileridine; | 25 | | (4) Bezitramide; | 26 | | (5) Bulk Dextropropoxyphene (non-dosage forms); |
| | | HB4352 | - 52 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (6) Dihydrocodeine; | 2 | | (7) Diphenoxylate; | 3 | | (8) Fentanyl; | 4 | | (9) Sufentanil; | 5 | | (9.5) Remifentanil; | 6 | | (10) Isomethadone; | 7 | | (11) (Blank); | 8 | | (12) Levorphanol (Levorphan); | 9 | | (13) Metazocine; | 10 | | (14) Methadone; | 11 | | (15) Methadone-Intermediate,
| 12 | | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane; | 13 | | (16) Moramide-Intermediate,
| 14 | | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| 15 | | acid; | 16 | | (17) Pethidine (meperidine); | 17 | | (18) Pethidine-Intermediate-A,
| 18 | | 4-cyano-1-methyl-4-phenylpiperidine; | 19 | | (19) Pethidine-Intermediate-B,
| 20 | | ethyl-4-phenylpiperidine-4-carboxylate; | 21 | | (20) Pethidine-Intermediate-C,
| 22 | | 1-methyl-4-phenylpiperidine-4-carboxylic acid; | 23 | | (21) Phenazocine; | 24 | | (22) Piminodine; | 25 | | (23) Racemethorphan; | 26 | | (24) (Blank); |
| | | HB4352 | - 53 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (25) Levo-alphacetylmethadol (some other names: | 2 | | levo-alpha-acetylmethadol, levomethadyl acetate, LAAM). | 3 | | (d) Unless specifically excepted or unless listed in | 4 | | another schedule, any material, compound, mixture, or | 5 | | preparation which contains any quantity of the following | 6 | | substances having a stimulant effect on the central nervous | 7 | | system: | 8 | | (1) Amphetamine, its salts, optical isomers, and salts | 9 | | of its optical isomers; | 10 | | (2) Methamphetamine, its salts, isomers, and salts of | 11 | | its isomers; | 12 | | (3) Phenmetrazine and its salts; | 13 | | (4) Methylphenidate; | 14 | | (5) Lisdexamfetamine. | 15 | | (e) Unless specifically excepted or unless listed in | 16 | | another schedule, any material, compound, mixture, or | 17 | | preparation which contains any quantity of the following | 18 | | substances having a depressant effect on the central nervous | 19 | | system, including its salts, isomers, and salts of isomers | 20 | | whenever the existence of such salts, isomers, and salts of | 21 | | isomers is possible within the specific chemical designation: | 22 | | (1) Amobarbital; | 23 | | (2) Secobarbital; | 24 | | (3) Pentobarbital; | 25 | | (4) Pentazocine; | 26 | | (5) Phencyclidine; |
| | | HB4352 | - 54 - | LRB103 35349 RLC 65413 b |
|
| 1 | | (6) Gluthethimide; | 2 | | (7) (Blank). | 3 | | (f) Unless specifically excepted or unless listed in | 4 | | another schedule, any material, compound, mixture, or | 5 | | preparation which contains any quantity of the following | 6 | | substances: | 7 | | (1) Immediate precursor to amphetamine and | 8 | | methamphetamine: | 9 | | (i) Phenylacetone | 10 | | Some trade or other names: phenyl-2-propanone; | 11 | | P2P; benzyl methyl ketone; methyl benzyl ketone. | 12 | | (2) Immediate precursors to phencyclidine: | 13 | | (i) 1-phenylcyclohexylamine; | 14 | | (ii) 1-piperidinocyclohexanecarbonitrile (PCC). | 15 | | (3) Nabilone. | 16 | | (4) Xylazine: N-(2,6-dimethylpheny1)-5,6-dihydro- | 17 | | 4H-1,3-thiazin-2-amine), including its isomers, esters, | 18 | | ethers, salts, and salts of isomers, esters, and ethers, | 19 | | whenever the existence of such isomers, esters, ethers, | 20 | | and salts is possible within the specific chemical | 21 | | designation as a Schedule II controlled substance. | 22 | | (g) Clonazolam. | 23 | | (Source: P.A. 100-368, eff. 1-1-18 .) | 24 | | Section 95. No acceleration or delay. Where this Act makes | 25 | | changes in a statute that is represented in this Act by text |
| | | HB4352 | - 55 - | LRB103 35349 RLC 65413 b |
|
| 1 | | that is not yet or no longer in effect (for example, a Section | 2 | | represented by multiple versions), the use of that text does | 3 | | not accelerate or delay the taking effect of (i) the changes | 4 | | made by this Act or (ii) provisions derived from any other | 5 | | Public Act. |
|